Atacand (Candesartan Cilexetil) Patent Expiration, LOE Window & CMS Spending

Atacand (Candesartan Cilexetil) by Ani: Off-Patent Genericized (AB Competition), 6 AB generics, $1.8M 2024 CMS Part D & Medicaid spend.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorAni
FDA Application & PathwayN020838 (NDA)
Exclusivity / Cliff HorizonOff-Patent Genericized (AB Competition)
Core Active-Ingredient LOE DateNot listed / N/A
Last Listed Patent or Exclusivity DateNot listed / N/A
Orange Book Patents (*PED Extensions)0 patents (0 *PED)
Active AB-Rated Generic Competitors6
2024 CMS Total Public Spend$1.8M
2024 Medicare Part D Spend$1.8M
2024 Medicaid Spend$35K
Reported Wholesale Price Change (CA SB 17)0 statutory filings in 2023 to 2026 panel